Insider Transactions in Q4 2021 at Verve Therapeutics, Inc. (VERV)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 28
2021
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
6,693
-1.62%
|
$261,027
$39.9 P/Share
|
|
Dec 28
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,693
+1.59%
|
$6,693
$1.39 P/Share
|
|
Dec 27
2021
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
42,000
-3.16%
|
$1,722,000
$41.16 P/Share
|
|
Dec 27
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
42,000
+8.56%
|
$42,000
$1.39 P/Share
|
|
Dec 23
2021
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
57,000
-12.3%
|
$2,223,000
$39.9 P/Share
|
|
Dec 23
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
57,000
+10.95%
|
$57,000
$1.39 P/Share
|
|
Dec 22
2021
|
Sekar Kathiresan Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
57,000
-3.19%
|
$2,166,000
$38.63 P/Share
|
|
Dec 22
2021
|
Sekar Kathiresan Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
57,000
+10.95%
|
$57,000
$1.39 P/Share
|
|
Dec 22
2021
|
Andrew Bellinger Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15,000
-34.82%
|
$570,000
$38.46 P/Share
|
|
Dec 22
2021
|
Andrew Bellinger Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+42.86%
|
$15,000
$1.48 P/Share
|
|
Dec 02
2021
|
Burt A Adelman |
BUY
Open market or private purchase
|
Indirect |
4,700
+50.0%
|
$145,700
$31.34 P/Share
|
|
Dec 02
2021
|
Andrew D. Ashe |
BUY
Open market or private purchase
|
Direct |
4,000
+2.29%
|
$128,000
$32.1 P/Share
|